Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Revestive

- PMLiVE

Takeda to acquire Nimbus’ TYK2 inhibitor in deal worth $6bn

NDI-034858 is under evaluation for the treatment of multiple autoimmune diseases

- PMLiVE

Takeda’s dengue vaccine receives EC approval

The decision follows a positive recommendation for Qdenga from the CHMP in October

- PMLiVE

Takeda’s Exkivity receives NICE recommendation for rare form of lung cancer

Patients with EGFR Exon20ins+ NSCLC make up approximately 2% of NSCLC cases

- PMLiVE

Takeda’s dengue vaccine candidate recommended for approval by CHMP

Dengue disease causes around 390 million infections and 500,000 hospitalisations each year

- PMLiVE

Takeda and Daiichi Sankyo collaborate to create wearable device

Takeda and Daiichi Sankyo have announced that they will work on a new research project, along with Tohoku University and MICIN, a digital health and telemedicine company, to develop a...

Takeda agrees on $2bn deal with Code Bio to expand its gene therapy programmes

The pharma company will gain opt-in rights for four rare diseases candidates

- PMLiVE

FDA rejects Takeda’s Eohilia after delays

After more than a year on ‘priority review’, the FDA has said it cannot approve Takeda’s budesonide oral suspension without a further clinical study

Improving Health Through Integrated & Personalized Patient Care

Hicham Naim, Global Head, Integrated & Personalized Patient Care Program, Digital Advisory Board at Takeda & Founder of Curated Health, explores digital medicine & biomarkers, outcomes-based business models, Software as...

Impetus Digital

- PMLiVE

Takeda and KSQ Therapeutics to develop immune-based cancer treatments

Collaboration will utilise KSQ’s CRISPR-screening technology

Effects of the Pandemic on Evidence Generation & Scientific Exchange

Farah Husein, Director, Evidence Generation, Canadian Centre of Excellence, at Takeda, discusses all things evidence generation, including the impact of the COVID-19 pandemic on HEOR, RWE, epidemiology, and PRO studies and...

Impetus Digital

- PMLiVE

Joint COVID-19 trial begins testing drugs from Amgen, UCB and Takeda

Trial will test therapeutic candidates in hospitalised COVID-19 patients

- PMLiVE

Takeda to sell Japan consumer health unit for $2.3bn

Deal helps to reduce debt accrued from Shire takeover

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links